Maria C Mendes-Correa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/313734/publications.pdf

Version: 2024-02-01

40 papers

2,139 citations

840776 11 h-index 34 g-index

47 all docs

47 docs citations

47 times ranked

4226 citing authors

#	Article	IF	CITATIONS
1	Evaluation of the Utilization of FilmArray Meningitis/Encephalitis in Children With Suspected Central Nervous System Infection. Pediatric Emergency Care, 2022, 38, 58-61.	0.9	3
2	Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2022, 64, e19.	1.1	9
3	Knowledge of Hepatitis C virus vertical transmission and subsequent pregnancy outcome in virus-positive female blood donors. Brazilian Journal of Infectious Diseases, 2022, 26, 102334.	0.6	O
4	Does hepatitis E deserve more attention?. Brazilian Journal of Infectious Diseases, 2022, 26, 102338.	0.6	0
5	Understanding SabiÃ; virus infections (Brazilian mammarenavirus). Travel Medicine and Infectious Disease, 2022, 48, 102351.	3.0	7
6	Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant. Clinics, 2022, 77, 100068.	1.5	2
7	COVID-19 salivary signature: diagnostic and research opportunities. Journal of Clinical Pathology, 2021, 74, 344-349.	2.0	62
8	Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols?. Medical Hypotheses, 2021, 146, 110436.	1.5	24
9	Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19. Journal of Oral Microbiology, 2021, 13, 1858002.	2.7	34
10	The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C. BMC Gastroenterology, 2021, 21, 81.	2.0	6
11	Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil. Infection and Drug Resistance, 2021, Volume 14, 723-730.	2.7	3
12	Decontamination and re-use of surgical masks and respirators during the COVID-19 pandemic. International Journal of Infectious Diseases, 2021, 104, 320-328.	3.3	12
13	Prolonged presence of replicationâ€competent SARSâ€CoVâ€2 in mildly symptomatic individuals: A report of two cases. Journal of Medical Virology, 2021, 93, 5603-5607.	5.0	7
14	Nucleoprotein-based ELISA for detection of SARS-COV-2 IgG antibodies: Could an old assay be suitable for serodiagnosis of the new coronavirus?. Journal of Virological Methods, 2021, 290, 114064.	2.1	16
15	Torquetenovirus in saliva: A potential biomarker for SARS-CoV-2 infection?. PLoS ONE, 2021, 16, e0256357.	2.5	12
16	Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers. Journal of Infection, 2021, , .	3.3	13
17	Clinical features and natural history of the first 2073 suspected COVID-19 cases in the Corona São Caetano primary care programme: a prospective cohort study. BMJ Open, 2021, 11, e042745.	1.9	27
18	SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients. Clinics, 2021, 76, e3548.	1.5	3

#	Article	IF	Citations
19	The Torque Teno Virus Titer in Saliva Reflects the Level of Circulating CD4+ T Lymphocytes and HIV in Individuals Undergoing Antiretroviral Maintenance Therapy. Frontiers in Medicine, 2021, 8, 809312.	2.6	6
20	Torquetenovirus Titer in Vaginal Secretions from Pregnant and Postpartum Women: Association with Absence of Lactobacillus crispatus and Levels of Lactic Acid and Matrix Metalloproteinase-8. Reproductive Sciences, 2020, 27, 2075-2081.	2.5	14
21	First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. Journal of Neurology, 2020, 267, 3154-3156.	3.6	104
22	Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. American Journal of Tropical Medicine and Hygiene, 2020, 103, 169-174.	1.4	6
23	Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Brazilian Journal of Infectious Diseases, 2019, 23, 182-190.	0.6	37
24	Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study. PLoS ONE, 2019, 14, e0226566.	2.5	О
25	Exploratory spatial analysis of HBV cases in Brazil between 2005 and 2017. Revista Brasileira De Epidemiologia, 2019, 22, e190007.	0.8	8
26	Characteristics of a hepatitis C patient cohort at a specialized tertiary care facility: Identifying criteria to improve the allocation of public health resources. Clinics, 2019, 74, e1286.	1.5	0
27	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Annals of Hepatology, 2018, 17, 959-968.	1.5	3
28	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir \hat{A}_{\pm} Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Annals of Hepatology, 2018, 17, 0-10.	1.5	0
29	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
30	Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV. Archives of Virology, 2017, 162, 165-169.	2.1	13
31	Resistance-Associated Variants in HCV Subtypes 1a and 1b Detected by Ion Torrent Sequencing Platform. Antiviral Therapy, 2016, 21, 653-660.	1.0	11
32	HCV inter-subtype 1a/1b recombinant detected by complete-genome next-generation sequencing. Archives of Virology, 2016, 161, 2161-2168.	2.1	9
33	Resistance Mutations are Rare among Protease Inhibitor Treatment-Naive Hepatitis C Genotype-1 Patients with or without HIV Coinfection. Antiviral Therapy, 2015, 20, 281-287.	1.0	16
34	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International, 2014, 8, 517-526.	4.2	6
35	Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil. BMC Infectious Diseases, 2011, 11, 247.	2.9	9
36	Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil. Brazilian Journal of Infectious Diseases, 2010, 14, 237-41.	0.6	6

#	Article	IF	CITATIONS
37	Hepatic Ultrastructural Mitochondrial Changes Prior to Antiretroviral Therapy in HIV-Infected Patients in Brazil. Journal of the International Association of Providers of AIDS Care, 2008, 7, 252-258.	1.2	5
38	Incidence and Predictors of Severe Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C in Brazil. AIDS Patient Care and STDs, 2008, 22, 701-707.	2.5	10
39	Clinical and histological characteristics of HIV and hepatitis C virus-co-infected patients in Brazil: a case series study. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2008, 50, 213-217.	1.1	4
40	Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster. Revista Do Instituto De Medicina Tropical De Sao Paulo, 0, 64, .	1.1	2